Jaguar Health, Inc. (NASDAQ: JAGX), the commercial-stage pharmaceuticals company, offers 100,000 common stock shares on a resale basis. On Tuesday, the company’s shares were trading 3.61% at $1.65 apiece.
In September 2020, the company launched new initiatives called Entheogen Therapeutics to support the development of psychoactive plant-based medicines for mood disorders, apart from other mental health issues. As many as 9.5% of adults from 18 years and beyond age group suffer depressive illnesses, such as dysthymia, bipolar disorder, and major depression, in America each year.
Financial report for Q1-2021
Meanwhile, the company has reported its first-quarter financial results. The gross and net sales of Mytesi came in at around $4.6 million, and $1.2 million, increasing 250% and 43%, respectively, compared to the previous year. Mytesi (crofelemer) is the symptomatic relief antidiarrheal drug for noninfectious diarrhea in patients having HIV/AIDS. Unit sales volume of the same drug increased by around 6% in Q1-2021 when seen against Q1-2020.
As far as Neonorm™, the animal-related drug is concerned, the sales remained the same as Q1-2020 due to lesser commercialization effort.
Other financial figures
In Q1-2021, the company reported $8.8 million of loss from operations against a $7.7 million loss in Q1-2020. This indicates a 15% increase in loss of $1.1 million on a quarter-over-quarter basis.
Meanwhile, net loss reported is $12.0 million in Q1-2021, compared with $7.9 million of net loss in Q1-2020, representing 51.3%, or $4.1 million increase on a quarter-over-quarter basis.
Non-GAAP EBITDA in Q1- 2021 was $9.0 million relative to Q1- 2020 net loss of $6.5 million.
Other expenses for Q1-2021, compared with Q1-2020, are here- Cost of Product Revenue $0.6 million as against $0.7 million, R&D expense was $2.4 million compared to $1.6 million. In comparison, Sales and Marketing expense came in at $2.1 million as against $1.5 million. G&A expense was reported at $3.4 million in Q1-2021 compared with $3.1 million in Q1-2020.